您的位置: 首页 > 农业专利 > 详情页

Fulvestrant complexes and their Derivatives, Process for their Preparation and Pharmaceutical compositions containing them
专利权人:
DRUGGABILITY TECHNOLOGIES HOLDINGS LIMITED
发明人:
ERZSBET RKA ANGI,TAMS SOLYMOSI,LSZL DR. MOLNR,GENOVVA DR. FILIPCSEI,KATALIN FERENCZI,RICHARD BALZS KRPTI,ZSOLT DR. TVS,ZSFIA DR. FENYVESI,HRISTOS DR. GLAVINAS,GBOR HELTOVICS
申请号:
ARP140104246
公开号:
AR098389A1
申请日:
2014.11.11
申请国别(地区):
AR
年份:
2016
代理人:
摘要:
2. A compound formula acceptable to the drug, including fullerene salt or salt, or its derivatives and the derivatives acceptable to the drug. 2. Preparation process and drug synthesis containing these materials. The formulation of the consortium has physical and chemical characteristics, They enable the compound to be obtained orally and used in the treatment of cervical cancer for the treatment of metabolically positive breast cancer in postmenopausal women treated with estrogen. Goal 1: a stable complex,1. it has the following characteristics: it contains active components selected from Fulvest Rant group, its salts or derivatives; at least one compound selected from polyethylene acrylic polyethylene polyethylene ethyl ester copolymer group; PVC; PVC; 1. Ethylene monomer copolymers and vinyl acetate, as well as polydicarboxylic acid (maieico Co metal vinyl ether);where said complex has at least one of the following properties: a) it can be instantly dispersed in relevant physiological media; b) has a higher dissolution rate; c) is stable in a solid form and in a colloidal solution and / or dispersion; d) has an apparent solubility in water of at least 1 mg / ml; e) presents an amorphous X-ray character in the solid form; f) has a PAMPA permeability of at least 0.5 x 10⁻⁶ cm / s when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease over time for at least 1 month;(g) Its main / typical absorption peak is at least 1412 cm 83151;1197 cm 83151 and 1105 cm 83151;1. The typical absorption peaks of 1611cm 83151 and 1504cm 83151 are missing;(h) The complex can be bioavailable by oral administration. Claim 2: the compound determined according to claim 1, which is characterized by the selection of a polyethylene ester (e.g. gelucire 44 / 14, gelucire 50 / 13) composed of monkey, diene and triglyceride, diene and diene from the glycerin of polyethylene glycol,Hydroxypropyl cellulose (e.g., klucell EF, klucell LF),1. Polyoximeros (ethylene oxide and pr
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充